
By Catherine Bouris and Sarah Spina-Matthews
Patients have more options with weight-loss tablets available for purchase, but experts warn that unless the stigma against people with obesity is addressed, they will always be hesitant to seek help.
Wegovy became Australia’s first weight-loss tablet to be cleared by the Therapeutic Goods Administration earlier in November, with the appetite-suppressing medication hitting pharmacy shelves on Friday.
University of Sydney pediatric expert Louise Baur hopes to see a world where obesity prevention is taken seriously, including acknowledging the factors that make it difficult for people to lose weight and keep it off.
These include the cost of effective therapies, access to informed clinical care and modern environments that make it easy for obesity to develop.
“Can we see a world where people living with obesity do not experience stigma on a regular basis in many parts of their life, including in the health system?” Professor Baur said on Friday.
Teacher and mother-of-six Kim Roberts, has been giving herself weekly weight-loss drug injections for the past three years after a heart attack led to the discovery of a genetic cholesterol condition.
She will switch to taking Wegovy as a daily tablet.
“It will just fit in with what I do on a day-to-day basis,” she told AAP.
Ms Roberts, 46, said the drug helped her manage her condition and lose about 30kg.
“I feel better. It’s also taught me how to eat better,” she said.
Experts acknowledge tablets give patients more options, but note that side effects and cost concerns remain the same across all forms of the medication.
“The considerations would mostly be up to personal preference,” Monash University obesity medicine expert Associate Professor Priya Sumithran said.
“There will be people who were really put off by the fact it was only available as an injection that might be more interested (now).”
Wegovy tablets will cost patients up to $5000 a year, though Professor Baur expects there to be changes to government subsidies of the medications.
“There are many more people I would love to see have subsidised access to medications … that will change with time, and it would be lovely to see more of it,” she said.
A second weight-loss pill, marketed as Foundayo, was recently also approved for sale in Australia.
The federal government is in negotiations with Wegovy’s manufacturer, Novo Nordisk, to bring it onto the scheme for a small cohort of patients.
It would bring the price down to $25 per script or $7.70 for concession card holders.
News all day, every day at CityNewsQBN.com.au.
Leave a Reply